ASCO 2022 Conference Coverage

 

ASCO 2022 Conference Coverage
V

ASCO 2022 on the Predictive Value of TGFβ1/TGFBR2 Ratio for Evaluating the Effectiveness of Treatment in DLBCL

By ASCO 2022 Conference Coverage FEATURING Valeria Bandovkina
By ASCO 2022 Conference Coverage FEATURING Valeria Bandovkina
0 views
June 21, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

03:38
Lilly Medical Affairs

SERDS: Relevance and Role in Current & Future Treatments for HR+…

Feat. K. Jhaveri

Featured Video

03:57
Lilly Medical Affairs

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Feat. K. Jhaveri
Lymphoma
04:26
ASCO 2022 Conference Coverage

2022 ASCO Annual Meeting "The Effects of AVM0703 Mobilization o…

Feat. J. Dalpez
01:07
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on the Phase 2 KEYNOTE-C11 Study: Sequen…

Feat. J. Winter
09:39
ASCO 2022 Conference Coverage

ASCO 2022 on the Phase 2 KEYNOTE-C11 Study: Sequential Pembro & …

Feat. J. Winter
01:13
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on the Phase III frontMIND Study: Tafasi…

Feat. U. Vitolo
08:45
ASCO 2022 Conference Coverage

ASCO 2022 on the Phase III frontMIND Study: Tafasitamab + Lenalidomi…

Feat. U. Vitolo
08:55
ASCO 2022 Conference Coverage

ASCO 2022 on the Analysis of Peripheral Neuropathy in 1L DLBCL Using…

Feat. M. Trneny
10:16
ASCO 2022 Conference Coverage

ASCO 2022 ADCs and CARs: Racing to Cure Aggresive Lymphoma

Feat. K. Patel
13:02
ASCO 2022 Conference Coverage

ASCO 2022 on the Predictive Value of TGFβ1/TGFBR2 Ratio for Evaluati…

Feat. V. Bandovkina
11:30
ASCO 2022 Conference Coverage

ASCO 2022 Expert Discussion: Current Treatment Approaches in Hemophi…

Feat. J. Bussel, C. Mcguinn
01:44
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Treatment Patterns and Real-World Effect…

Feat. M. Di
05:39
ASCO 2022 Conference Coverage

ASCO 2022 Treatment Patterns and Real-World Effectiveness of Rituxim…

Feat. M. Di
05:16
ASCO 2022 Conference Coverage

ASCO 2022 Three-Year Follow-Up of Outcomes With KTE-X19 in R/R Mantl…

Feat. M. Wang
53
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Three-Year Follow-Up of Outcomes With KT…

Feat. M. Wang
05:40
ASCO 2022 Conference Coverage

ASCO 2022 Brexucabtagene Autoleucel for R/R Mantle Cell Lymphoma: Re…

Feat. P. Jain
57
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Brexucabtagene Autoleucel for R/R Mantle…

Feat. P. Jain
07:46
ASCO 2022 Conference Coverage

ASCO 2022 on the Initial Safety Run-in Results of the Phase III POLA…

Feat. M. Matasar
03:32
ASCO 2022 Conference Coverage

ASCO 2022 Correlates of Common Concerns in Older Cancer Survivors of…

Feat. M. Loh
52
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Real World Experience of Combined Treatm…

Feat. M. Kalac
12:56
ASCO 2022 Conference Coverage

ASCO 2022 Real World Experience of Combined Treatment With Romidepsi…

Feat. M. Kalac
01:33
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Bendamustine Rituximab vs. Ibrutinib as …

Feat. J. Abeykoon
10:06
ASCO 2022 Conference Coverage

ASCO 2022 Bendamustine Rituximab vs. Ibrutinib as Primary Therapy fo…

Feat. J. Abeykoon
42
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Clinical & PROs in a Phase III, R…

Feat. J. Westin
05:27
ASCO 2022 Conference Coverage

ASCO 2022 on Clinical & PROs in a Phase III, Randomized, Open-La…

Feat. J. Westin
04:35
ASCO 2022 Conference Coverage

ASCO 2022 on CRC-403: A Phase 1/2 Study of bbT369, A Dual Targeting …

Feat. F. Locke
34
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Updated Interim Analysis of the Randomiz…

Feat. C. Lee Batlevi
05:16
ASCO 2022 Conference Coverage

ASCO 2022 Updated Interim Analysis of the Randomized Phase 1b/3 Stud…

Feat. C. Lee Batlevi
05:13
ASCO 2022 Conference Coverage

ASCO 2022 PACIFIC Trial Updates: Response Kinetics, Safety & Eff…

Feat. R. Steiner